Centers for Disease Control and Prevention. Mortality patterns: preliminary data, United States, 1996. MMWR
Morb Mortal Wkly Rep.1997;46:941-944.
Paffenbarger Jr RS, Wing AL, Hyder T. Physical activity
as an index of heart attack risk in college alumni. Am J
Epidemiol.1978;108:161-175.
Blair SN, Kohl III HW, Paffenbarger Jr RS, Clark DG, Cooper KG, Gibbons LW. Physical fitness and all-cause mortality: a
prospective study of healthy men and women. JAMA.1989;262:2395-2401.
Lee IM, Hsieh CC, Paffenbarger Jr RS. Exercise intensity
and longevity in men: the Harvard Alumni Study. JAMA.1995;273:1179-1184.
Blair SN, Kohl III HW, Barlow CE, Paffenbarger Jr RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause
mortality. JAMA.1995;273:1093-1098.
Blair SN, Kampert JB, Kohl III HW.
et al. Influences of
cardiorespiratory fitness and other precursors on cardiovascular
disease and all-cause mortality in men and women. JAMA.1996;276:205-210.
Kushi LH, Fee RM, Folsom AR, Mink PJ, Anderson KE, Sellers TA. Physical activity and mortality in postmenopausal women. JAMA.1997;277:1287-1292.
Kujala UM, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the
Finnish twin cohort. JAMA.1998;279:440-444.
Hakim AA, Petrovitch H, Burchfiel CM.
et al. Effects of
walking on mortality among nonsmoking retired men. N Engl J
Med.1998;338:93-94.
National Institutes of Health Consensus Development
Panel on Physical Activity and Cardiovascular Health. Physical activity
and cardiovascular health. JAMA.1996;276:241-246.
American College of Sports Medicine. Physical activity,
physical fitness, and hypertension: position stand. Med Sci Sports
Exerc.1993;25:1-10.
Blair SN. Evidence for success of exercise in
weight loss and control. Ann Intern Med.1993;119:702-706.
Stefanick ML, Wood PD. Physical activity, lipid and
lipoprotein metabolism, and lipid transport. In: Bouchard C, Shephard
RJ, Stephens T, eds. Physical Activity, Fitness, and Health:
International Proceedings and Consensus StatementChampaign, Ill:
Human Kinetics Publishers Inc; 1994:417-431.
Mayer-Davis EJ, D'Agostino Jr R, Kerter AJ.
et al. Intensity and amount of physical activity in relation to insulin
sensitivity: the insulin resistance atherosclerosis study. JAMA.1998;279:669-674.
Van Der Wal AC, Das PK, Van De Berg DB, Van Der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ
immunophenotypic analysis suggesting an immune mediated response. Lab Invest.1989;61:166-170.
Munro JM, Cotran RS. Biology of disease: the
pathogenesis of atherosclerosis, atherogenesis and inflammation. Lab Invest.1988;58:249-261.
Libby P, Hansson GK. Biology of disease involvements of
the immune system in human atherogenesis: current knowledge and
unanswered questions. Lab Invest.1991;64:5-15.
Ross R. The pathogenesis of atherosclerosis: a
perspective for the 1990s. Nature.1993;362:801-809.
Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is
atherosclerosis an immunologically mediated disease? Immunol
Today.1995;16:27-33.
Yokota T, Hansson GK. Immunological mechanisms in
atherosclerosis. J Intern Med.1995;238:479-489.
Watanabe T, Haraoka S, Shimokama T. Inflammatory and
immunological nature of atherosclerosis. Int J Cardiol.1996;54(suppl):S51-S60.
Selwyn AP, Kinlay S, Ganz P. Atherogenesis and
ischemic heart disease. Am J Cardiol.1997;80:3H-7H.
Wick G, Romen M, Amberger A.
et al. Atherosclerosis,
autoimmunity, and vascular-associated lymphoid tissue. FASEB
J.1997;11:1199-1207.
Campbell JH, Campbell GR. The cell biology of
atherosclerosis: new developments. Aust N Z J Med.1997;27:497-500.
Adam E, Melnick JL, Probtsfield JL.
et al. High levels of cytomegalovirus antibody in patients requiring vascular
surgery for atherosclerosis. Lancet.1987;2:291-293.
Yamashiroya HM, Ghosh L, Yang R, Robertson Jr AL. Herpesviridae in the coronary arteries and aorta of young trauma
victims. Am J Pathol.1988;130:71-79.
Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of
young adults (15-34 years old). Proc Natl Acad Sci U S A.1995;92:6911-6914.
Witztum JL. Immunological responses to oxidized LDL. Atherosclerosis.1997;131:S9-S11.
Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in
transplanted human hearts. JAMA.1997;278:1169-1175.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in
apparently healthy men. N Engl J Med.1997;336:973-979.
Danesh J, Collins R, Appleby P, Petro R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte
count with coronary artery disease: meta-analyses of prospective
studies. JAMA.1998;279:1477-1482.
Muscari A, Bozzoli C, Puddu GM.
et al. Association of
serum C3 levels with the risk of myocardial infarction. Am J
Med.1995;98:357-364.
Borish L, Rosenwasser LJ. Update on cytokines. J
Allergy Clin Immunol.1996;97:719-733.
Te Velde AA, Huijbens RJF, Heije K, de Vries JE, Fidgor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1α, tumor
necrosis factor α, and IL-6 by human monocytes. Blood.1990;76:1392-1397.
Elliot MJ, Gamble JR, Park LS, Vadas MA, Lopez AE. Inhibition of human monocyte adhesion by interleukin-4. Blood.1991;12:2739-2745.
Fenton MJ, Buras JA, Donnelly RP. IL-4
reciprocally regulates IL-1 and IL-1 receptor antagonist expression in
human monocytes. J Immunol.1992;149:1283-1288.
Vasse M, Paysant J, Soria J, Mirshahi S, Vannier JP, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10
and IL-13. Br J Haematol.1996;93:955-961.
Krakauer T. IL-10 inhibits the adhesion of leukocyte
cells to IL-1 activated human endothelial cells. Immunol Lett.1995;45:61-65.
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated
macrophages. J Immunol.1991;147:3815-3822.
Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation
by interleukin 10. J Exp Med.1991;174:1549-1555.
Grazinelli TT, Oswald IP, James SL, Sher A. IL-10
inhibits parasite killing and nitrogen production by IFNγ-activated
macrophages. J Immunol.1992;148:1792-1799.
D'Andrea A, Aste-Amezaga M, Vaiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human
lymphocyte interferon-γ production by suppressing natural killer cell
stimulatory factor/IL-12 synthesis in accessory cells. J Exp
Med.1993;178:1041-1048.
Uyemura K, Demer LL, Castle SC.
et al. Cross-regulatory
roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin
Invest.1996;97:2130-2138.
Vadas MA, Gamble JR, Rye K, Barter P. Regulation of
leucocyte-endothelial interactions of special relevance to
atherogenesis. Clin Exp Pharmacol Physiol.1997;24:A33-A35.
Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC. Transforming growth factor beta is sequestered into an inactive pool by
lipoproteins. J Lipid Res.1997;38:2344-2352.
Tashiro H, Shimokawa H, Yamamoto K, Momohara M, Tada H, Takeshita A. Altered plasma levels of cytokines in patients with
ischemic heart disease. Coron Artery Dis.1997;8:143-147.
Reckless J, Metcalfe JC, Granger DJ. Tamoxifen
decreases cholesterol sevenfold and abolishes lipid lesion development
in apolipoprotein E knockout mice. Circulation.1997;95:1542-1548.
Angles-Cano E. Structural basis for the
pathophysiology of lipoprotein (a) in the athero-thrombotic process. Braz J Med Biol Res.1997;30:1271-1280.
Di Febbo C, Baccante G, Reale M.
et al. Transforming growth factor beta induces IL-1 receptor antagonist
production and gene expression in rat vascular smooth muscle cells. Atherosclerosis.1998;136:377-382.
Takami S, Yamashita S, Kihara S.
et al. Lipoprotein (a)
enhances the expression of intercellular adhesion molecule-1 in
cultured human umbilical vein endothelial cells. Circulation.1998;97:721-728.
Maluish AE, Strong DM. Lymphocyte proliferation. In:
Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical
ImmunologyWashington, DC: American Society for Microbiology;
1986:274-281.
Farrar MA, Schreiber RD. The molecular cell biology of
interferon-γ and its receptor. Annu Rev Immunol.1993;11:571-611.
Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out
mice. J Clin Invest.1997;99:2752-2761.